Hot topics close

CreditAccess Grameen Second Quarter 2025 Earnings: EPS Misses Expectations

CreditAccess Grameen Second Quarter 2025 Earnings EPS Misses Expectations
CreditAccess Grameen ( NSE:CREDITACC ) Second Quarter 2025 Results Key Financial Results Revenue: ₹5.49b (down 25% from...

CreditAccess Grameen (NSE:CREDITACC) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₹5.49b (down 25% from 2Q 2024).
  • Net income: ₹1.86b (down 46% from 2Q 2024).
  • Profit margin: 34% (down from 48% in 2Q 2024). The decrease in margin was driven by lower revenue.
  • EPS: ₹11.67 (down from ₹21.82 in 2Q 2024).
earnings-and-revenue-growth
NSEI:CREDITACC Earnings and Revenue Growth October 27th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

CreditAccess Grameen EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%.

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Consumer Finance industry in India.

Performance of the Indian Consumer Finance industry.

The company's shares are down 4.3% from a week ago.

Valuation

Our analysis of CreditAccess Grameen based on 6 different valuation metrics shows it might be undervalued. Discover what analysts are forecasting and how the current share price shapes up by clicking here.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

News Archive
  • Sanofi Pasteur
    Sanofi Pasteur
    Conjugate Vaccines Market Quality & Quantity Analysis | CSL Limited, Sanofi Pasteur, Astellas Pharma Inc
    7 Oct 2021
    1
  • Martin Lemay
    Martin Lemay
    BPM Sports Martin Lemay s'excuse pour des propos « inappropriés ...
    9 May 2024
    2
  • Conference League
    Conference League
    Late goal by El Kaabi gives Olympiakos Europa Conference League ...
    29 May 2024
    6
  • Canada vs Mexico
    Canada vs Mexico
    'Top of the table': The world reacts to Canada's historic 'Iceteca' win over Mexico in World Cup qualifier
    16 Nov 2021
    1
  • Allison Williams
    Allison Williams
    Allison Williams, Tony Goldwyn, and More Come Together for Star ...
    26 Oct 2023
    2
  • Digestion
    Digestion
    So THAT'S Why Your Stomach Hurts More As You Get Older
    1 Oct 2023
    1
This week's most popular news